Metabolomics of Empagliflozin after acute MI

The prognosis of patients suffering from acute myocardial infarction improved over the past deacades mainly due to immediate revascularisation using coronary angiography and stent implantation. Moreover, medical treatment has improved during that period, too. However, a significant and clinically meaningful increased risk for the development of heart failure within the following months and years remains as the heart does not recover well enough. The Austria-based multicenter trial EMMY, led by Harald Sourij and Dirk von Lewinski from the Medical University of Graz, revealed promising results using the SGLT2-inhibitor Empagliflozin. 476 patients were randomized to either Empagliflozin or placebo within 72 hours after acute myocardial infarction and maintained onthis therapy for 26 weeks. The study revealed significant improvement of the primary endpoint NTproBNP as well as for structural and functional parameters of the left ventricle in patients treated with Empagliflozin. The data was presented as Late-Breaking science at the ECS congress in Barcelona 2022 and simultaneously published in the European Heart Journal. From then the study attracted a lot of attention and is already cited in the ESC guidelines for Acute Coronary Syndromes as well as the one for Diabetes. Biosamples and detailed patients data is now analysed with respect to predictive metabolomic parameters as well as metabolomic changes under therapy. The research is conducted in close cooperations with Joanneum Research, Graz, and external partners at the Medical University Vienna plus INSERM and the University Descartes, Paris.